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The pharmacodynamics of dosage regimens of piperacillin alone or in combination with tazobactam against
piperacillin-resistant or -susceptible bacteria were studied in an in vitro model of infection. Experiments were
conducted by using a fixed daily exposure of 12 g of piperacillin, given as 3 g alone or in combination with
tazobactam at 0.375 g every 6 h, or the same total dose of the combination given as 4 g of piperacillin plus 0.5
g of tazobactam every 8 h. The addition of tazobactam to piperacillin, irrespective of the dosing interval, did
not alter the killing of piperacillin-susceptible organisms (Escherichia coli J53 and Pseudomonas aeruginosa
ATCC 27853). In contrast, experiments with an isogenic TEM-3-containing transconjugant of E. coli J53 (E.
coli J53.2-TEM-3) that was resistant to piperacillin (MIC, 128 ,g/ml) showed that the addition of tazobactam
resulted in bacterial killing similar to that observed with the wild-type strain. Although tazobactam
concentrations fell to less than 4 mg/liter (the concentration associated with a reduction in the piperacillin
MIC from 128 to 2 mg/liter) 2 to 3 h after a dose, a similar degree of bacterial killing was observed when the
same total 24-h dose of piperacillin-tazobactam was fractionated into dosing intervals of every 6 or 8 h.
Investigations with Staphylococcus aureus 7176 (piperacillin MIC, 128 ,Ig/ml) showed that the addition of
tazobactam, again irrespective of dosing interval, also resulted in net bacterial killing which was not seen with
piperacillin alone. These data support the use of extended dosing intervals (every 8 h) of piperacillin-
tazobactam in the treatment of infections caused by piperacillin-resistant bacteria.
Piperacillin, an extended-spectrum penicillin, has been used
for more than a decade in the treatment of mixed aerobic-
anaerobic bacterial infections. The dissemination of P-lacta-
mase-producing bacteria that inactivate piperacillin has de-
creased the clinical utility of this drug. One strategy used to
counteract the problems associated with 3-lactamase-produc-
ing bacteria has been the development of ,-lactamase inhibi-
tors such as clavulanic acid, sulbactam, and most recently,
tazobactam (19).
Tazobactam is a triazolymethyl penicillanic acid sulfone
which possesses very little intrinsic antibacterial activity (14).
When tazobactam is combined with piperacillin, it significantly
enhances the in vitro susceptibility of piperacillin against
,-lactamase-producing isolates of members of the family En-
terobacteriaceae, Staphylococcus spp., and Bacteroides spp. (1,
7, 8, 10, 11, 13, 14, 16, 18, 25).
Although the pharmacokinetic and pharmacodynamic pa-
rameters associated with optimal killing of gram-negative
aerobic bacteria have been well characterized for P-lactam
antibiotics (6), strategies for the design of dosage regimens of
,-lactam-,-lactamase inhibitor combinations are not estab-
lished. The question is relevant since dosage regimens of
P-lactamase inhibitor combinations provide concentrations of
inhibitor in vivo that exceed the breakpoint concentrations
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t Present address: Department of Pharmacy Practice, University of
Kansas Medical Center, Kansas City, KS 66103.
used in in vitro susceptibility testing of combinations for only 2
to 3 h.
The purpose of the study described here was to compare the
pharmacodynamics of various dosage regimens of a fixed daily
exposure of piperacillin alone and in combination with tazo-
bactam against piperacillin-resistant or -susceptible bacteria in
an in vitro model of infection.
MATERIALS AND METHODS
Bacteria. The following strains were studied: Pseudomonas
aeruginosa ATCC 27853, a stable clinical isolate of methicillin-
susceptible Staphylococcus aureus 7176 obtained from a patient
with bacteremia, and an isogenic pair of Escherichia coli strains,
the wild type (J53) and the transconjugant possessing the
plasmid (J53.2-TEM-3) coding for the TEM-3 extended-spec-
trum P-lactamase (24).
Susceptibility testing. Table 1 shows the MICs of piperacil-
lin and piperacillin-tazobactam for the test strains. The strains
were selected on the basis of their susceptibilities or resistance
to piperacillin. E. coli J53.2-TEM-3 and S. aureus 7176 were
piperacillin resistant, but all strains were susceptible to pip-
eracillin-tazobactam (Table 1). MICs were determined by the
tube broth macrodilution method with an inoculum of -5 x
105 CFU/ml by standardized methods (21). The approved
susceptibility breakpoints of the National Committee for Clin-
ical Laboratory Standards (22) were used when such criteria
existed.
Antibiotics. Piperacillin powder for injection (lot 317-704)
and tazobactam analytical powder (lot 6818B46) were supplied
by Lederle Laboratories, Pearl River, N.Y.
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TABLE 1. MICs and MBCs for bacteria tested in the model
Piperacillin MIC/MBC (mg/liter)
Strain With tazobactam
Piperacillin alone (4 mg/liter)
E. coli J53 4/16 2/4
E. coli J53.2-TEM-3 128/128 2/2
S. aureus 7176 128/256 2/8
P. aeruginosa ATCC 27853 8/256 8/256
Media. Mueller-Hinton broth (MHB; Difco Laboratories,
Detroit, Mich.) supplemented with calcium (50 ,ug/ml) and
magnesium (25 ,ug/ml) (MHB-S) was used for all susceptibility
and model experiments.
In vitro model. Hollow-fiber bioreactor chambers (Cell
Pharm Mini-Bioreactor System; Unisyn Fibertec Corporation,
San Diego, Calif.) were connected in series to a central
compartment in an incubator as described previously (17). The
volume of each peripheral chamber was 15 ml of 10% heat
inactivated human serum-90% MHB-S. The central compart-
ment diluent was MHB-S. Following administration of a dose
of piperacillin or piperacillin-tazobactam, drug was eliminated
by pumping drug-free MHB-S into the central compartment at
a rate adjusted for human pharmacokinetic properties. The
elimination half-lives of piperacillin and tazobactam in the in
vitro model were adjusted to -1 h (12).
The bacteria used for all experiments were prepared from
inocula grown previously, divided into aliquots, and frozen in a
mixture of brain heart infusion broth-fetal calf serum (60:40).
On the day of an experiment, the frozen inoculum was thawed,
diluted with fresh MHB-S, and incubated for 1.5 h to bring the
bacteria into the growth phase. The bacteria were then injected
into the peripheral compartments of the model and were
incubated for 1 to 1.5 h to reach a target inoculum of -2 x 106
CFU/ml.
Dosage regimens. Experiments with piperacillin mono-
therapy were conducted by using a fixed 24-h exposure of 12 g,
with doses given as 3 g every 6 h. Piperacillin-plus-tazobactam
experiments used a fixed 24-h exposure of 12 g of piperacillin
with 1.5 g of tazobactam. This amount was fractionated into 2
dosage regimens of 3 g of piperacillin plus 0.375 g of tazobac-
tam every 6 h or 4 g of piperacillin plus 0.5 g of tazobactam
every 8 h. Doses were given as a simulated intravenous bolus in
all regimens.
Pharmacodynamic and pharmacokinetic measurements.
Samples (1 to 1.5 ml) were collected from the central and
peripheral compartments of the model every 2 to 4 h over a
24-h period. All samples from the peripheral chambers were
quantified for the number of bacterial CFU per milliliter.
Samples from the central and peripheral compartments of the
model were assayed for tazobactam and/or piperacillin content
by high-pressure liquid chromatography (23). The lower limits
of quantitation for piperacillin and tazobactam were 1 and 10
,ug/ml, respectively. The ranges of five standards for each drug
were 1 to 50 ,ug/ml for piperacillin and 10 to 50 ,ug/ml for
tazobactam. The within- and between-day coefficients of vari-
ation for three seeded controls of piperacillin (15 to 45
mg/liter) ranged between 7.2 and 10% (20 to 26 determina-
tions of each control). For tazobactam, controls of between 15
and 45 mg/liter had within- and between-day coefficients of
variation of between 15 and 22% (7 to 15 determinations for
each control). Experimental samples with drug concentrations
greater than the ranges of the standards were diluted into the
range of the curve. A one-compartment pharmacokinetic
model was fit to drug concentrations in the central compart-
ment measured following the first and last doses of both drugs
for all regimens by using extended least-squares regression
(MKMODEL, version 4; Biosoft, Milltown, N.J.).
Bacterial counts (CFU per milliliter) were determined by
serially diluting the sample 10-fold in cold saline and inoculat-
ing it (in triplicate) onto drug-free Mueller-Hinton agar (MHA)
with subsequent incubation at 37°C for 18 to 24 h. The
pharmacokinetics of the drugs in the model and the sampling
schedule resulted in little or no carryover of drug. The most
drug that was carried over during the processing for CFU per
milliliter counts was 7.5 mg of piperacillin per liter in experi-
ments with piperacillin alone against piperacillin-resistant bac-
teria; in view of the high MICs for these strains (128 mg/liter),
this amount would have a negligible effect on the recovery of
bacteria. Small numbers of bacteria (i.e., .1,000 CFU/ml)
were counted by placing 100 ,ul of sample into -10 ml of cold
saline and filtering this mixture through a 0.45-,um-pore-size
filter (Millipore Corporation, Bedford, Mass.). The filter was
washed several times with sterile saline and was then placed
directly onto MHA and incubated, and the colonies were
counted; thus, the theoretical limit of detection for this method
is 10 CFU/ml. The dilution of the sample into saline and
washing with an additional 5 to 10 ml makes it unlikely that
significant amounts of drug are transferred with bacteria on the
filter to MHA. In all experiments, samples collected at 0 and 24
h were also processed on MHA containing 128 jig of piperacil-
lin per ml and 128 and 4 ,ug of piperacillin-tazobactam per ml,
respectively, to quantify drug-resistant bacterial subpopula-
tions. The MICs for all strains were determined before the
model experiments and for posttreatment isolates (24 h)
recovered on drug-free MHA plates.
Post-p-lactamase inhibition effect. In separate experiments
with static drug concentrations, a ca. 106 inoculum of growing
E. coli J53.2-TEM-3 was exposed for 2 h to the integral mean
(area under the concentration-time curve from 0 to 2 h
[AUCO2]/2) concentrations of drug obtained in the model of
tazobactam alone or tazobactam combined with piperacillin.
Following a 2-h exposure, the bacteria were washed three
times and were resuspended in prewarmed medium containing
either piperacillin alone or piperacillin combined with tazobac-
tam at mean integral concentrations of drug simulated in the
model 2 to 8 h after a dose (i.e., AUC2_8/6). Samples were
taken hourly and were processed for bacterial counts as
described above.
RESULTS
Pharmacokinetics. Figure 1 depicts the simulated and mea-
sured piperacillin and tazobactam concentrations in the central
compartment of the model. The mean piperacillin concentra-
tions of samples collected simultaneously from the central and
peripheral compartments of the model were within 5 to 20% of
each other, indicating rapid equilibration between the central
and peripheral compartments. Mean piperacillin pharmacoki-
netic parameters are displayed in Table 2. In experiments that
assessed the pharmacodynamics of piperacillin given as 3 g
every 6 h against piperacillin-resistant bacteria, the piperacillin
concentrations measured in the central and peripheral com-
partments were lower than targeted concentrations but still
within acceptable ranges (data not shown). This was expected,
however, because of bacterial production of ,-lactamase and
the inactivation of piperacillin, which led to "sink" conditions
in the model.
For the test strains susceptible to piperacillin alone or
piperacillin combined with tazobactam, piperacillin concentra-
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FIG. 1. Simulated (lines) and measured (points) concentrations of
piperacillin (A) and tazobactam (B) in the central compartment of the
in vitro model. Simulated concentrations for piperacillin were derived
by using pharmacokinetic parameters generated from fits of individual
experiments for which the data are given in Table 2, whereas tazobac-
tam concentrations were generated from values reported in the
literature. The measured drug concentrations are means for two to
four samples. The regimens were piperacillin given as 3 g every 6 h
(A), piperacillin and tazobactam given as 3 and 0.375 g, respectively,
every 6 h (V), and piperacillin and tazobactam given as 4 and 0.5 g,
respectively, every 8 h (0).
tions exceeded the MIC for 63 to 100% of a 24-h dosing cycle
with all regimens (Table 2). In contrast, experiments with
piperacillin alone against piperacillin-resistant bacteria (i.e.,
E. coli J-53-TEM-3 and S. aureus 7176) resulted in concentra-
tions of piperacillin greater than the starting MICs (128
mg/liter) for only 17% of a 24-h period.
Mean peak tazobactam concentrations in the central com-
partment for 3 g of piperacillin plus 0.375 g of tazobactam
every 6 h and 4 g of piperacillin plus 0.5 g of tazobactam were
27.4 and 39.0 ,ug/ml, respectively. The mean elimination half-
lives for 3 g of piperacillin plus 0.375 g of tazobactam every 6
h and 4 g of piperacillin plus 0.5 g of tazobactam were 1.3 and
1.2 h, respectively. The concentrations of tazobactam exceeded
4 mg/liter for c50% of a 24-h dosing cycle with either regimen.
Pharmacodynamics. All bacterial strains tested in the model
grew well during control experiments (no drug exposure).
(i) E. coli J53. The first dose of all regimens resulted in a
TABLE 2. Piperacillin and tazobactam pharmacokinetic parameters
in central compartment of in vitro model according to regimen
Piperacillin Piperacillin Piperacillin
Drug and parameter" (3 g) eve(ybactam (0.375 g) bactam (0.5 g)
every 6 h every 8 h
Piperacillin
AUC (mg h/liter)" 366.7 388.2 488.9
Cm. (mg/liter) 227.6 235.7 366.7
tj/2 (h) 1.2 1.3 1.3
% Time > MICC
E. coli J-53 100 100 83
E. coli J-53-TEM-3 17 100 83
P. aeruginosa 27853 83 83 63
S. aureus 7176 17 100 83
Tazobactam
AUC (mg h/liter)" NAd 42.5 64.7
Cm. (mg/L) NA 27.6 36.5
t1/2 (h) NA 1.3 1.3
% Time > 4 mg/liter NA 50 38
a All parameters for piperacillin and the maximum concentration of tazobac-
tam in serum are based on measured concentrations; the other tazobactam
parameters are based on target simulations. AUC, area under the concentration-
time curve; Cm.,,, maximum concentration of drug in serum; t112, half-life.
b Per dose.
cPercentage of 24-h period that drug concentrations exceeded the value
shown for each regimen.
d NA, not applicable.
marked bactericidal effect; on average, a 4-log-unit reduction
in the number of CFU per milliliter occurred within the first
dosing interval (Fig. 2A). Mean bacterial counts of -10
CFU/ml were achieved with all regimens by the end of the
second dosing interval. There was no difference in bacterial
killing with either regimen of piperacillin-tazobactam from
that observed with piperacillin monotherapy.
Experiments with piperacillin alone against E. coli J53-
TEM-3 showed the effect of the inactivating enzyme on
pharmacodynamic properties (Fig. 2B). Although E. coli J53-
TEM-3 was resistant, the piperacillin MIC for the strain was
exceedec in the model for -2 h, thus resulting in only transient
bacterial killing and then the regrowth of bacteria fully resis-
tant to the piperacillin concentrations obtained in the model.
The numbers of bacteria recovered on drug-free MHA and
MHA with 128 mg of piperacillin per liter were identical.
The addition of tazobactam to piperacillin restored the
bacterial killing of the ,B-lactamase-producing isogenic strain of
E. coli (J53.2-TEM-3) by piperacillin to that observed with the
parent strain (Fig. 2B). There was no difference in bacterial
killing when the fixed daily exposure of piperacillin-tazobactam
was fractionated into dosing intervals of every 6 or 8 h. When
samples collected at 24 h from the piperacillin monotherapy
experiment were grown on drug-containing MHA to quantify
drug-resistant subpopulations, the entire inoculum was resis-
tant to 128 ,ug of piperacillin per ml; however, no growth was
seen on plates containing 128 and 4 ,ug of piperacillin and
tazobactam per ml, respectively. The MICs for posttreatment
bacteria (24 h) recovered on drug-free MHA were unchanged.
Experiments with static concentrations of drugs designed to
mimic the same time-averaged exposure did not demonstrate a
post-,-lactamase inhibition effect; bacterial killing occurred
only when tazobactam was present in the culture at the same
time as piperacillin.
(ii) S. aureus 7176. Piperacillin monotherapy resulted in
approximately a 1.5-log-unit reduction in the number of CFU
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FIG. 2. Pharmacodynamics of piperacillin (PiP) alone or in combi-
nation with tazobactam (TAZO) against E. coli J53 (A) and E. coli
J53.2-TEM-3 (B) in an in vitro model of infection. Datum points are
geometric means ± standard deviations for three to six within-day
replications. The regimens were piperacillin given as 3 g every 6 h
(q6h) (A), piperacillin and tazobactam given as 3 and 0.375 g,
respectively, every 6 h (q6h) (V), and piperacillin and tazobactam
given as 4 and 0.5 g, respectively, every 8 h (q8h) (0).
per milliliter over 2 h; this was followed by bacterial regrowth
(Fig. 3A). In contrast, both piperacillin-tazobactam regimens
were highly active against this strain. There was no difference
in bacterial killing when the fixed daily exposure of piperacil-
lin-tazobactam was fractionated into dosing intervals of every 6
and 8 h. Subpopulation analysis and the posttreatment MICs
obtained from the piperacillin monotherapy experiment were
comparable to the results obtained for the other P-lactamase-
producing strain.
(iii) P. aeruginosa ATCC 27853. All regimens of piperacillin
alone or combined with tazobactam resulted in a 4-log-unit
reduction in the number of CFU per milliliter during the first
dosing interval (Fig. 3B). As was seen with E. coli J53, the
addition of tazobactam had no effect on piperacillin pharma-
codynamics. Killing was fairly consistent between regimens
until the 14-h time point, when 2 log units of bacterial regrowth
occurred with the piperacillin monotherapy regimen. When
samples collected at 24 h from the piperacillin monotherapy
experiment were grown on MHA containing 128 ,ug of pi-
peracillin per ml no growth occurred. The MICs for posttreat-
ment bacteria recovered on drug-free MHA were unchanged.
DISCUSSION
When using 3-lactamase inhibitor combinations, it is impor-
tant that an adequate amount of inhibitor be provided in vivo
to inactivate the 13-lactamases produced by actively growing
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FIG. 3. Pharmacodynamics of piperacillin (PiP) alone or in combi-
nation with tazobactam (TAZO) against S. aureus 7176 (A) and P.
aeruginosa ATCC 27853 (B). The regimens were piperacillin given as
3 g every 6 h (q6h) (A), piperacillin and tazobactam given as 3 and
0.375 g, respectively, every 6 h (q6h) (V), and piperacillin and
tazobactam given as 4 and 0.5 g, respectively, every 8 h (q8h) (0).
bacteria at the site of infection. Livermore (15) has proposed
that the activities of various ,B-lactam-3-lactamase inhibitor
combinations be determined by assessment of the concentra-
tion of inhibitor required to bring the susceptibilities of
individual organisms to below accepted susceptibility break-
points for the ,-lactam alone or even to the susceptibilities for
3-lactamase-negative, wild-type strains. Since inactivation of
,-lactamases follows stoichiometry on the basis of turnover of
the enzyme, the amount of [3-lactamase inhibitor necessary to
augment the activity of a P-lactam in vivo would be based on
the provision of an adequate amount of inhibitor provided over
time, or the AUC. Failure to deliver adequate amounts of
inhibitor would be expected to result in resistance to the drug
combination, including bacterial regrowth at the end of a
dosage interval. Resistance to 1-lactam-P-lactamase inhibitor
combinations has been described in certain strains of E. coli
that hyperproduce the TEM-1 1-lactamase, and hence have a
relative insufficiency of inhibitor (15, 16).
The results of the present study indicate that a simulated
fixed daily exposure of piperacillin-tazobactam given as divided
doses every 6 or 8 h results in similar pharmacodynamic effects
against a piperacillin-resistant E. coli strain and S. aureus in the
model. Despite extended periods of concentrations of tazobac-
tam less than the fixed concentration used in in vitro suscep-
tibility testing (4 mg/liter), the bactericidal activity of piperacil-
lin-tazobactam against TEM-3-producing E. coli was similar to
that observed for piperacillin monotherapy against ,B-lacta-
mase-negative E. coli J53.
The prolonged bactericidal effects of the combination
A
/0N DRUG 3gL 6 -
/ IPAZO -3/.375g q6h
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against 3-lactamase-producing bacteria in the model might be
explained by several mechanisms. Studies with tazobactam and
other inhibitors indicate that its inactivation of 3-lactamase is
characterized by turnover rates of enzyme and inhibitor (4).
Therefore, it is conceivable that several hours of an essentially
,B-lactamase-negative state may occur in bacteria following
exposure to high levels of an inhibitor, until the production of
enzyme by the persisting bacteria reaches levels sufficient to
inactivate a significant proportion of the 1-lactam. This period
could result in a prolonged period of susceptibility of the
bacteria to low concentrations of a ,-lactam. Thorburn and
Molesworth (27) reported a "post-,-lactamase inhibition ef-
fect" in which regrowth of amoxicillin-resistant bacteria was
prevented for several hours by amoxicillin alone following a
brief exposure to and then removal of amoxicillin plus clavu-
lanic acid. Furthermore, Cavalieri et al. (5) reported augmen-
tation of the antimicrobial effects of ,B-lactams by inhibitors in
an animal model, even when the ,B-lactams were given up to 3.5
h after a single dose of the inhibitor. However, in the limited
experiments conducted with the piperacillin-resistant strain of
E. coli (J53-TEM-3), bacterial killing occurred only when
tazobactam was present in the cultures, suggesting no post-,-
lactamase inhibition effect of static concentrations of the
combination of drugs against this strain. This result is consis-
tent with previous observations with other ,B-lactam-,-lacta-
mase inhibitor combinations (9).
As simulated in the model, 1-lactamase inhibitor concentra-
tions in vivo fall below the concentrations used for in vitro
testing of combinations of 3-lactam--i-lactamase inhibitor
within 2 to 3 h after a dose. For tazobactam, concentrations in
plasma exceed 4 mg/liter only up to 3 h after a dose. However,
the AUCO24 for tazobactam in the model was -2 times
greater than the amount of inhibitor that is available during
incubation during susceptibility testing. This exposure profile
was sufficient to enable bacterial killing by piperacillin in the
model similar to that observed for the ,B-lactamase-negative
isogenic strain. It appears that in vivo the AUC for an inhibitor
is the important parameter for the activities of combinations
with 3-lactamase inhibitors against ,B-lactamase-producing
bacteria. Thus, it is possible to prolong the dosage interval of
a ,B-lactam-P-lactamase inhibitor combination for a finite
period that is limited by the reaccumulation of the ,-lactamase
produced by persisting bacteria to levels that exceed the
number of molecules of an inhibitor available to inactivate the
,-lactamase.
The strategy of using prolonged dosage intervals of inhibitor
combinations may not apply in all cases. Others have shown
the rapid regrowth of bacteria in vitro after exposure to
ticarcillin-clavulanic acid, removal of clavulanic acid, and re-
suspension in ticarcillin alone (9). Some strains with multiple
copies of plasmids that hyperproduce ,B-lactamase or combi-
nations of inhibitors with more labile 3-lactams may not be
amenable to prolonged inhibition of growth with extended
dosage intervals.
The results of the present study show that the combination
of piperacillin-tazobactam given as a daily exposure of 12 g of
piperacillin and 1.5 g of tazobactam fractionated into dosage
intervals of every 6 or 8 h resulted in similar degrees of
bacterial killing under conditions that simulated the pharma-
cokinetics in humans in the in vitro model of infection used in
the study. These results are concordant with human studies of
4 g of piperacillin plus 0.5 g of tazobactam every 8 h to patients
with intra-abdominal infections, lower respiratory tract infec-
tions, and skin and soft-tissue infections (3, 20, 26) and suggest
that further clinical evaluation of extended dosage intervals of
this combination in humans is warranted.
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